EYPT - EyePoint pharmaceuticals

-

$undefined

N/A

(N/A)

EyePoint pharmaceuticals NasdaqGM:EYPT EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Location: 480 Pleasant Street, Watertown, MA, 02472, United States | Website: https://eyepointpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

202M

Cash

318.2M

Avg Qtr Burn

-37.04M

Short % of Float

16.71%

Insider Ownership

3.54%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
YUTIQ Details
Chronic non-infectious uveitis

Approved

Quarterly sales

DEXYCU Details
Post-operative inflammation

Approved

Quarterly sales

DURAVYU™ (vorolanib intravitreal insert) (EYP-1901) Details
Macular degeneration, Wet age-related macular degeneration

Phase 3

Data readout

DURAVYU (EYP-1901) Details
Diabetic macular edema

Phase 3

Initiation

EYP-1901 Details
Non-proliferative diabetic retinopathy

Failed

Discontinued